CNDP2 Antibody

What is CNDP2 and what are its known biological functions?

CNDP2 (Carnosine dipeptidase II, also known as cytosolic non-specific dipeptidase) primarily catalyzes peptide bond hydrolysis in dipeptides, with a non-redundant activity toward threonyl dipeptides. This metallopeptidase of the M20 family has high dipeptidase activity toward cysteinyl glycine, an intermediate metabolite in glutathione metabolism . CNDP2 also metabolizes N-lactoyl-amino acids, both through hydrolysis to form lactic acid and amino acids, and through their formation by reverse proteolysis . Beyond its enzymatic functions, CNDP2 plays important roles in cell cycle regulation and apoptosis .

What molecular weights should researchers expect when detecting CNDP2?

When working with CNDP2 antibodies, researchers should be aware of potential isoform variations:

• Calculated molecular weight: 53 kDa

• Observed molecular weight range: 44-53 kDa

• CNDP2 has two documented isoforms with molecular weights of 53 and 44 kDa

This variation is important to consider when interpreting Western blot results, as band patterns may differ depending on tissue type and experimental conditions.

What is the tissue distribution pattern of CNDP2?

CNDP2 isoform 1 is ubiquitously expressed with notably higher levels in the kidney and liver at the protein level. It is also expressed in peripheral blood leukocytes . Expression has been documented in gastric mucosa, where it is reportedly down-regulated in gastric cancer tissues . When designing experiments, researchers should consider this differential expression pattern, particularly when selecting appropriate positive controls.

Experimental Applications and Methodologies

Different CNDP2 antibodies have been validated on various biological samples:

For Western Blot:

• Human cell lines: HepG2, LNCaP, HEK-293T, HL-60, Jurkat, PC-3, U-251, U-937, HeLa

• Animal tissues: Mouse kidney, rat kidney

For Immunoprecipitation:

• Mouse testis tissue

For Immunohistochemistry:

• Human testis tissue

• Human kidney and skeletal muscle

For Immunofluorescence:

• HeLa cells

This information helps researchers select the most appropriate positive controls for their experiments.

What dilutions are recommended for different experimental applications?

Optimal antibody dilutions vary by application and should be empirically determined for each experimental system:

As noted by manufacturers: "It is recommended that this reagent should be titrated in each testing system to obtain optimal results" .

What antigen retrieval methods are recommended for CNDP2 immunohistochemistry?

For optimal immunohistochemical detection of CNDP2:

• Primary recommendation: TE buffer pH 9.0

• Alternative method: Citrate buffer pH 6.0

Researchers should evaluate both methods when optimizing protocols for new tissue types or fixation conditions.

How should CNDP2 antibodies be stored to maintain optimal activity?

For maximum antibody stability and performance:

• Storage temperature: -20°C

• Expected stability: One year after shipment

• Storage buffer: PBS with 0.02% sodium azide and 50% glycerol pH 7.3

• Note: Aliquoting is unnecessary for -20°C storage

Some preparations may contain 0.1% BSA in the 20 μl sizes .

How can researchers distinguish between CNDP2 isoforms in experimental data?

When analyzing CNDP2 expression:

• Consider running gradient gels to better separate the 44 kDa and 53 kDa isoforms

• Include positive controls from tissues known to express specific isoforms (kidney and liver preferentially express isoform 1)

• When possible, use isoform-specific antibodies or primers (for RT-PCR)

• Document the observed molecular weight and compare with expected ranges (44-53 kDa)

This approach helps in accurately interpreting variations in band patterns across different experimental samples.

How can researchers utilize CNDP2 knockdown/knockout models effectively?

CNDP2 knockdown and knockout models have been successfully employed in multiple publications . When designing such studies:

• Consider the potential compensatory mechanisms in complete knockout models

• For transient knockdown, validate silencing efficiency at both mRNA and protein levels

• Monitor both enzymatic activity (dipeptidase function) and non-enzymatic effects (cell cycle regulation, apoptosis)

• Include rescue experiments with wild-type CNDP2 to confirm phenotype specificity

• When studying specific pathways, consider targeting particular isoforms based on their tissue distribution

These approaches help establish clear connections between CNDP2 function and observed phenotypes.

What is the relationship between CNDP2 and glutathione metabolism in research models?

CNDP2 exhibits high dipeptidase activity toward cysteinyl glycine, an intermediate metabolite in glutathione metabolism . When investigating this relationship:

• Monitor glutathione (GSH) levels in conjunction with CNDP2 expression/activity

• Measure cysteinyl glycine concentrations as a direct substrate

• Consider oxidative stress parameters in CNDP2 manipulation experiments

• Evaluate expression patterns in conditions with altered glutathione metabolism

• Investigate potential regulatory feedback between GSH levels and CNDP2 expression

This multi-parameter approach provides insights into CNDP2's role in cellular redox homeostasis.

How should researchers address contradictory findings in CNDP2 expression studies?

When faced with conflicting CNDP2 expression data across studies:

• Carefully compare antibody specifications (epitope regions, validation methods)

• Consider tissue-specific and isoform-specific expression patterns

• Evaluate methodology differences (sample preparation, detection methods)

• Examine pathological context (disease state, medication status)

• Verify findings using orthogonal approaches (protein vs. mRNA detection)

• Account for potential post-translational modifications affecting antibody recognition

This systematic approach helps resolve apparent contradictions and contributes to a more accurate understanding of CNDP2 biology.

What strategies can researchers employ when facing weak or non-specific CNDP2 antibody signals?

When encountering signal issues with CNDP2 antibodies:

For weak signals:

• Adjust antibody concentration within recommended ranges (e.g., 1:2000-1:12000 for WB)

• Optimize protein loading amount (start with 20-40 μg for cell lysates)

• Extend primary antibody incubation time (overnight at 4°C)

• Verify sample integrity and CNDP2 expression in the specific model

For non-specific signals:

• Increase blocking time or concentration (5% BSA or milk)

• Optimize washing steps (more frequent changes, longer durations)

• Consider alternative antibodies targeting different epitopes

• Include appropriate positive and negative controls in every experiment

How can researchers validate CNDP2 antibody specificity?

To ensure antibody specificity:

• Use multiple antibodies targeting different CNDP2 epitopes and compare results

• Include CNDP2 knockdown/knockout samples as negative controls

• Perform peptide competition assays with the immunogenic peptide

• Compare observed patterns with published expression profiles (higher expression in kidney and liver)

• Validate critical findings using orthogonal approaches (mass spectrometry, RNA analysis)

This multi-faceted validation approach increases confidence in the specificity of observed signals.

What are the critical considerations when selecting between different CNDP2 antibodies?

When choosing between available CNDP2 antibodies:

• Match the antibody's species reactivity to your experimental model (human, mouse, rat, etc.)

• Consider the epitope location relative to functional domains or isoform-specific regions

  • Middle region antibodies (e.g., ABIN2787096)

  • C-terminal region antibodies (e.g., ab101406)

• Evaluate validation data for your specific application (WB, IHC, IF, IP)

• Review published literature using the specific antibody clone

• Consider polyclonal vs. monoclonal options based on your research needs

This strategic selection process helps ensure optimal antibody performance for specific experimental requirements.

How might CNDP2 function relate to emerging research in metabolic disorders?

Given CNDP2's role in dipeptide metabolism and glutathione pathways , researchers might consider:

• Investigating CNDP2 expression and activity in models of metabolic syndrome, diabetes, or obesity

• Exploring the relationship between CNDP2 function and oxidative stress in metabolic disorders

• Examining potential interactions with metabolic signaling pathways (mTOR, AMPK)

• Determining if CNDP2 polymorphisms correlate with metabolic disease susceptibility

• Developing tissue-specific CNDP2 modulation approaches for metabolic intervention studies

These avenues may reveal new connections between dipeptide metabolism and systemic metabolic regulation.

What novel techniques could advance CNDP2 research beyond traditional antibody applications?

Beyond conventional antibody applications, researchers should consider:

• CRISPR-based tagging of endogenous CNDP2 for live-cell imaging and dynamics studies

• Proximity labeling approaches to identify novel CNDP2 interaction partners

• Single-cell analysis of CNDP2 expression across heterogeneous tissues

• Computational modeling of CNDP2 enzymatic activity and substrate specificity

• Development of activity-based probes to monitor CNDP2 function in real-time